Fate Therapeutics, Inc., which is based in San Diego, CA, received a $15 million grant tied to RECLAIM-LN, a phase 2 clinical trial with expected enrollment of 53.

The trial’s primary endpoint is the proportion of participants achieving complete renal response, or CRR, at Week 26.

FT819 is the company’s off-the-shelf CD19-targeting CAR T-cell product candidate.

ประเด็นสำคัญ

  • The grant award is worth $15 million and goes to Fate Therapeutics, Inc..
  • RECLAIM-LN is a phase 2 clinical trial with expected enrollment of 53.
  • FT819 is described as an off-the-shelf CD19-targeting CAR T-cell product candidate.